Sharon Marshall Ordover

Sharon Marshall Ordover

Board Member

Sharon Marshall Ordover is an attorney with over 40 years of experience as a general counsel, corporate executive and board member. In her professional career, she has focused on leveraging her legal expertise and business acumen to drive corporate objectives and growth for the companies she is affiliated with. Sharon’s legal experience is diverse and includes corporate transactional work, such as mergers, acquisitions, and joint ventures; complex financing arrangements; employment-related law; intellectual property, corporate governance and compliance; risk management; insurance; and real estate.  

Sharon started her legal career in the health care department of the law firm of Epstein, Becker & Green, New York, New York where she specialized in health care transactions, managed care, regulations and compliance.   

Sharon then moved into the corporate sector where she served as General Counsel to three different companies. Most recently, Sharon was the SVP, General Counsel of Evergreen Trading, a corporate trading company located in New York, New York, with revenues in excess of $300 million.  

Sharon holds a juris doctor from Benjamin N. Cardozo School of Law, New York, New York, a master’s in social work from Wurzweiler School of Social Work, New York, New York and a bachelor of arts from Clark University, Worcester, Massachusetts where she majored in Psychology. She also holds Certificates in Mediation and Divorce Mediation from the New York Center for Interpersonal Development.  

Sharon’s past Board affiliations include Secretary/Treasurer and Board Member of Beineinu NYC, Inc., a 501(c)(3) not for profit corporation;  President and Board Member of the 230 Riverside Condominium; and Secretary of Evergreen Trading.   

As a Board Member of FACTMS, Sharon is delighted to combine her extensive legal experience and social work background with her passion for social impact to support the vision and mission of FACTMS to raise awareness and educate about TMS while expanding access to this life-altering treatment.